Adcendo

biotech · Copenhagen, DK

Clinical-stage biotech developing antibody-drug conjugates for cancer.

Founders

Lars Henning Engelholm (Denmark · ♂) — A cancer researcher at Copenhagen's Finsen Laboratory, Engelholm co-founded Adcendo to translate his lab's discoveries on the uPARAP receptor into antibody-drug conjugate cancer therapies.
Niels Behrendt (Denmark · ♂) — A scientific co-founder and Finsen Laboratory professor whose research underpins Adcendo, Behrendt spun the company out of the University of Copenhagen to develop targeted ADC cancer drugs.
Christoffer Nielsen (DK · ♂) — A scientist from the Finsen Laboratory and University of Copenhagen, Nielsen co-founded Adcendo to translate uPARAP receptor research into antibody-drug conjugates for cancer.
Henrik Stage (DK · ♂) — A biotech entrepreneur, Stage co-founded Adcendo to commercialize the University of Copenhagen spin-out's antibody-drug conjugate pipeline.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Nov 2024	Series B Adcendo closed an oversubscribed $135M Series B led by TCGX to advance its antibody-drug conjugate pipeline through clinical development.	$135M
Jun 2024	Series A Copenhagen biotech Adcendo raised a €16M Series A extension led by Dawn Biopharma, bringing its Series A total to €98M.	$17.3M
Apr 2023	Series A Copenhagen biotech Adcendo raised an additional EUR31M, extending its Series A to EUR82M, led by Pontifax.	$33.5M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.